Investopedia: The Week Ahead In Healthcare

Whether you want to call it the pause that refreshes or the calm before the storm, investors should not expect as much news from the med-tech industry over the next few weeks. That said, business continues and investors still have data and information to process.

Lilly - Somewhere Between a Home Run and a Bunt 
Lilly (NYSE:LLY) reported last week that its Alzheimer's drug candidate solanezumab showed decidedly mixed performance in pivotal studies of mild-to-moderate patients. Like bapineuzumab, the drug that Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) were attempting to develop for Alzheimer's, solanezumab failed to meet its primary endpoints. Unlike bapi, though, this drug seemed to slow the pace of decline in patients with mild cases.

Continue here:
http://stocks.investopedia.com/stock-analysis/2012/The-Week-Ahead-In-Healthcare-LLY-BMY-IDIX-GILD0827.aspx